Gelesis Holdings, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Boston--(business wire)---- $gls #earnings--a new paper published today in cell reports medicine suggests that weight loss resulting from gelesis' superabsorbent hydrogel treatment is not only a result of its space-occupying properties; the mechanical composition and structure of the material may have notable benefits for gut and metabolic health. the continued rise in obesity and type 2 diabetes has led to the increasing prevalence of fatty liver disease worldwide and highlights the urgent need for therapies tha.

Boston--(business wire)--gelesis holdings, inc. (nyse: gls) (“gelesis” or the “company”), the maker of plenity for weight management, today reported financial results for the third quarter of 2022. plenity is a novel orally administered, fda-cleared weight management therapy that helps people feel satisfied with smaller portions, so they can eat less and lose weight, while still enjoying the foods they love. plenity is the only fda-cleared aid for weight management for people with a bmi as low as 25, up to a bmi of 40, with the largest addressable market of any prescription weight management approach on the market today. “we continued to see strong uptake of plenity among consumers and physicians in the third quarter with 114% topline growth this quarter compared to the prior year period as well as 36% of additional gross margin...

Boston--(business wire)--gelesis holdings inc. (nyse: gls) (“gelesis” or the “company”) the maker of plenity for weight management, today announced dr. frank greenway will give an oral presentation at obesity week in san diego, on wednesday, november 2 at 4:00pm pdt.

Boston--(business wire)--gelesis (nyse: gls), the maker of plenity for weight management, today reported financial results for the second quarter of 2022. “we are seeing both consumers and clinicians embracing plenity, with continued growth in both of our distribution channels. we are excited by the fact that consumers are ordering quarterly kits at the start of their treatment journey as well as by our refill rates,” said yishai zohar, founder and ceo of gelesis. “there has been incredible momentum in obesity care and finally, patients have multiple effective approaches to managing their weight based upon their bmi, insurance coverage, and their personal needs. plenity offers a unique solution: orally administered capsules for those individuals with overweight and obesity across a wide bmi spectrum, including those that are looking to lose 15-30 pounds...

Boston--(business wire)--gelesis (nyse: gls), the maker of plenity® for weight management, today announced that the company will report financial results for the first quarter ended march 31, 2022, on may 12, 2022 following the market close. gelesis management will host a live conference call and webcast at 4:30 p.m. et on the same day to discuss the results. conference call details date: thursday, may 12, 2022 time: 4:30 p.m. eastern time toll-free dial-in number: (844) 200-6205 international

Gelesis Holdings, Inc. (NYSE:GLS ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Anna Kate Heller - IR Yishai Zohar - Founder and CEO Elliot Maltz – CFO Conference Call Participants Daniel Grosslight - Citi Operator Hello, and welcome to the Gelesis Third Quarter 2022 Earnings Conference Call. My name is Elliot, and I'll be coordinating your call today.

BOSTON--(BUSINESS WIRE)--Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today announced Dr. Frank Greenway will give an oral presentation at Obesity Week in San Diego, on Wednesday, November 2 at 4:00pm PDT.

Gelesis Holdings, Inc. (NYSE:GLS ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Anna Heller - IR Yishai Zohar - Founder & CEO Elliot Maltz - CFO David Pass - COO & CCO Conference Call Participants Operator Hello, everyone. And welcome to the Gelesis' Second Quarter 2022 Earnings Conference Call.

Gelesis Holdings, Inc. (NYSE:GLS ) Q1 2022 Earnings Conference Call May 1, 2022 4:30 PM ET Company Participants Yishai Zohar – Founder and Chief Executive Officer Elliot Maltz – Chief Financial Officer David Pass – Chief Operating and Commercial Officer Conference Call Participants Ellie Merle – UBS Operator Good afternoon, everyone, and thank you for participating in today's conference call to discuss Gelesis' financial results for the fiscal quarter ended March 31, 2022. Joining us today are Yishai Zohar, Founder and CEO of Gelesis; and Elliot Maltz, CFO of Gelesis.

BOSTON--(BUSINESS WIRE)--Gelesis (NYSE: GLS), the maker of Plenity® for weight management, today announced that the Company will report financial results for the First Quarter ended March 31, 2022, on May 12, 2022 following the market close. Gelesis management will host a live conference call and webcast at 4:30 p.m. ET on the same day to discuss the results. Conference Call Details Date: Thursday, May 12, 2022 Time: 4:30 p.m. Eastern Time Toll-free dial-in number: (844) 200-6205 International

Gelesis Holdings is the developer of proprietary biomimetic superabsorbent hydrogels for weight loss. The Company is evaluating and investigating its technology in GI-related diseases.

Gelesis Holdings, Inc. (GLS) CEO Yishai Zohar on Q4 2021 Results - Earnings Call Transcript

BOSTON--(BUSINESS WIRE)---- $GLS #earnings--Gelesis (NYSE: GLS), the maker of Plenity® for weight management, today announced that the Company will report financial results for fiscal year 2021 on March 24, 2022, following the market close. Gelesis management will host a live conference call and webcast at 4:30 p.m. ET on the same day to discuss the results. The live conference call webcast can be accessed on the Gelesis Investor Relations website at https://ir.gelesis.com/. The webcast will also be archived and